Osteosarcoma Gene-Edited Cell Lines for Drug Discovery

Osteosarcoma is the most common primary malignant bone tumor, with an annual global incidence of approximately 3.4 per million person-years (WHO, 2020). It predominantly affects adolescents and young adults, with a second peak in older adults over 60. The 5-year survival rate for localized osteosarcoma is about 60-70%, but drops to 15-30% for patients with metastatic or recurrent disease (NCI, 2023). Key risk factors include Paget's disease, prior radiation therapy, and certain genetic syndromes such as Li-Fraumeni syndrome (TP53 mutations) and hereditary retinoblastoma (RB1 mutations).

Osteosarcoma is an ideal model for mechanistic studies due to its high genomic instability, complex karyotypes, and well-characterized subtypes (conventional, telangiectatic, small cell, etc.). Public datasets from TCGA and COSMIC provide extensive mutation and expression data. Open questions include the role of tumor heterogeneity, metastasis mechanisms, and resistance to chemotherapy, making gene-edited cell models essential for functional validation.

• • Osteosarcoma pathogenesis involves disruption of several key pathways:
• • TP53 pathway: Loss of p53 function leads to genomic instability and impaired apoptosis.
• • RB1 pathway: Inactivation of RB1 allows uncontrolled cell cycle progression.
• • PI3K/AKT/mTOR pathway: Hyperactivation promotes cell survival and proliferation.
• • Wnt/beta-catenin pathway: Aberrant signaling contributes to osteoblast differentiation blockade.
• • Steps in TP53 pathway disruption:

1. Mutation or deletion of TP53 gene.

2. Loss of p53 protein function.

3. Failure to activate DNA repair or apoptosis.

4. Accumulation of genomic alterations.

| Gene | Frequency (%) | Mutation Type | Functional Effect |

|------|---------------|---------------|-------------------|

| TP53 | 50-70 | Missense, nonsense, deletion | Loss of tumor suppressor activity |

| RB1 | 10-30 | Deletion, nonsense | Cell cycle dysregulation |

| MYC | 10-20 | Amplification | Increased proliferation |

| CDKN2A | 10-15 | Deletion | Loss of cell cycle control |

| ATRX | 10-15 | Mutation | Alternative lengthening of telomeres |

Data from TCGA (Cancer Genome Atlas Research Network, 2017) and COSMIC (Sanger Institute).

• • Key signaling networks in osteosarcoma:
• • PI3K/AKT/mTOR pathway: Hyperactivation via PTEN loss or PIK3CA mutation.
• • MAPK/ERK pathway: Driven by RAS or RAF mutations.
• • Wnt/beta-catenin pathway: Beta-catenin stabilization and nuclear translocation.
• • Notch signaling: Altered expression of NOTCH receptors and ligands.
• • IGF signaling: IGF1R overexpression promotes growth and metastasis.
• • Key nodes:
• • TP53: Central regulator of DNA damage response.
• • RB1: Gatekeeper of G1/S transition.
• • MYC: Transcription factor driving proliferation.
• • PTEN: Negative regulator of PI3K signaling.

| Cell Line | Origin | Key Mutations |

|-----------|--------|---------------|

| HOS | Primary osteosarcoma | TP53 mutant, KRAS mutant |

| MG-63 | Primary osteosarcoma | TP53 wild-type, RB1 mutant |

| U-2 OS | Primary osteosarcoma | TP53 wild-type, RB1 wild-type |

| Saos-2 | Primary osteosarcoma | TP53 null, RB1 mutant |

| 143B | Metastatic variant of HOS | TP53 mutant, KRAS mutant |

Organoids derived from patient samples offer advantages such as 3D architecture, cell-cell interactions, and better recapitulation of tumor heterogeneity. They are increasingly used for drug screening and personalized medicine studies.

• • Common animal models for osteosarcoma:
• • Patient-derived xenografts (PDX): Implantation of human tumor tissue into immunodeficient mice.
• • Genetically engineered mouse models (GEMM): Conditional TP53 and RB1 knockout in osteoblasts.
• • Induced models: Injection of osteosarcoma cell lines (e.g., 143B) into tibia or tail vein for metastasis studies.
• • Syngeneic models: Use of mouse osteosarcoma cell lines (e.g., K7M2) in immunocompetent mice.

• • CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. Examples include:
• • TP53 knockout in U-2 OS or MG-63 cells to study loss of tumor suppressor function.
• • KRAS G12D knock-in in HOS cells to model oncogenic activation.
• • RB1 deletion in Saos-2 cells to investigate cell cycle dysregulation.
• • Commercially available, sequence-verified gene-edited models accelerate research by providing consistent, validated tools for functional genomics and drug discovery. These models are available from commercial sources and can be customized for specific mutations.

• • CRISPR knockout and knock-in lines are used to validate the role of specific genes in osteosarcoma. For example:
• • TP53 knockout in U-2 OS cells confirms its role in chemoresistance.
• • MYC amplification knock-in in MG-63 cells demonstrates its effect on proliferation.
• • ATRX knockout in Saos-2 cells reveals its function in telomere maintenance.

• • Isogenic pairs (e.g., TP53 wild-type vs. knockout) are used to identify drug sensitivities and resistance mechanisms. For example:
• • Screening of PARP inhibitors in TP53-deficient vs. wild-type cells.
• • Modeling resistance to doxorubicin by serial exposure in gene-edited lines.
• • Testing of targeted therapies (e.g., mTOR inhibitors) in PTEN knockout models.

• • CRISPR synthetic lethality screens identify genes that are essential only in the context of specific mutations. For example:
• • Screening for genes that become essential in TP53-null osteosarcoma cells.
• • Identification of WEE1 as a synthetic lethal target in RB1-deficient cells.
• • Validation of novel biomarkers for early detection or prognosis.